Reference for Chapter 38: Graft‐versus‐host Disease

1 Dignan FL, Amrolia P, Clark A, et al. Diagnosis and management of chronic graft‐versus‐host disease. Br J Haematol 2012;158(1):46–61. Cross Ref link Pubmed link
2 Dignan FL, Clark A, Amrolia P, et al. Diagnosis and management of acute graft‐versus‐host disease. Br J Haematol 2012;158(1):30–45. Cross Ref link Pubmed link
3 Pasquini MC, Voltarelli J, Atkins HL, et al. Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2012;18(10):1471–8. Cross Ref link Pubmed link
4 Sui W, Hou X, Che W, et al. Hematopoietic and mesenchymal stem cell transplantation for severe and refractory systemic lupus erythematosus. Clin Immunol 2013;148(2):186–97. Cross Ref link Pubmed link
5 Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11(12):945–56. Cross Ref link Pubmed link
6 Warren EH, Deeg HJ. Dissecting graft‐versus‐leukemia from graft‐versus‐host‐disease using novel strategies. Tissue Antigens 2013;81(4):183–93. Cross Ref link Pubmed link
7 Jaglowski SM, Devine SM. Graft‐versus‐host disease: why have we not made more progress? Curr Opin Hematol 2014;21(2):141–7. Cross Ref link Pubmed link
8 Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft‐versus‐host disease and for chronic graft‐versus‐host disease according to National Institutes of Health consensus criteria. Blood 2011;117(11):3214–19. Cross Ref link Pubmed link
9 Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft‐versus‐host disease. Br J Haematol 1987;67(4):397–406. Cross Ref link Pubmed link
10 Hahn T, McCarthy PL Jr, Zhang MJ, et al. Risk factors for acute graft‐versus‐host disease after human leukocyte antigen‐identical sibling transplants for adults with leukemia. J Clin Oncol 2008;26(35):5728–34. Cross Ref link Pubmed link
11 Baird K, Pavletic SZ. Chronic graft versus host disease. Curr Opin Hematol 2006;13(6):426–35. Cross Ref link Pubmed link
12 Carlens S, Ringden O, Remberger M, et al. Risk factors for chronic graft‐versus‐host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998;22(8):755–61. Cross Ref link Pubmed link
13 Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft‐versus‐host disease after allogeneic blood stem cell transplantation. Blood 2001;98(6):1695–700. Cross Ref link Pubmed link
14 Nakamura R, Forman SJ. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence‐based GVHD prophylaxis. Expert Rev Hematol 2014 (in press).
15 Hymes SR, Alousi AM, Cowen EW. Graft‐versus‐host disease: part I. Pathogenesis and clinical manifestations of graft‐versus‐host disease. J Am Acad Dermatol 2012;66(4):515 e1–18; quiz 533–4. Cross Ref link Pubmed link
16 Ferrara JL, Levine JE, Reddy P, Holler E. Graft‐versus‐host disease. Lancet 2009;373(9674):1550–61. Cross Ref link Pubmed link
17 Collin M, Jardine L. A question of persistence: Langerhans cells and graft‐versus‐host disease. Exp Dermatol 2014;23(4):234–5. Cross Ref link Pubmed link
18 Mavin E, Ahmed SS, O'Boyle G, et al. Regulatory T cells inhibit CD8(+) T‐cell tissue invasion in human skin graft‐versus‐host reactions. Transplantation 2012;94(5):456–64. Cross Ref link Pubmed link
19 Patriarca F, Skert C, Sperotto A, et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft‐vs‐host disease and immune recovery. Exp Hematol 2006;34(3):389–96. Cross Ref link Pubmed link
20 Quaranta S, Shulman H, Ahmed A, et al. Autoantibodies in human chronic graft‐versus‐host disease after hematopoietic cell transplantation. Clin Immunol 1999;91(1):106–16. Cross Ref link Pubmed link
21 Shimada M, Onizuka M, Machida S, et al. Association of autoimmune disease‐related gene polymorphisms with chronic graft‐versus‐host disease. Br J Haematol 2007;139(3):458–63. Pubmed link
22 Hess AD, Horwitz L, Beschorner WE, Santos GW. Development of graft‐vs.‐host disease‐like syndrome in cyclosporine‐treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti‐Ia specificity, including autoreactivity. J Exp Med 1985;161(4):718–30. Cross Ref link Pubmed link
23 Hollander GA, Widmer B, Burakoff SJ. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease. J Immunol 1994;152(4):1609–17. Pubmed link
24 Teshima T, Reddy P, Liu C, et al. Impaired thymic negative selection causes autoimmune graft‐versus‐host disease. Blood 2003;102(2):429–35. Cross Ref link Pubmed link
25 Tsoi MS, Storb R, Dobbs S, et al. Cell‐mediated immunity to non‐HLA antigens of the host by donor lymphocytes in patients with chronic graft‐vs‐host disease. J Immunol 1980;125(5):2258–62. Pubmed link
26 Wu T, Young JS, Johnston H, et al. Thymic damage, impaired negative selection, and development of chronic graft‐versus‐host disease caused by donor CD4+ and CD8+ T cells. J Immunol 2013;191(1):488–99. Cross Ref link Pubmed link
27 Shimabukuro‐Vornhagen A, Hallek MJ, Storb RF, von Bergwelt‐Baildon MS. The role of B cells in the pathogenesis of graft‐versus‐host disease. Blood 2009;114(24):4919–27. Cross Ref link Pubmed link
28 Sarantopoulos S, Stevenson KE, Kim HT, et al. Recovery of B‐cell homeostasis after rituximab in chronic graft‐versus‐host disease. Blood 2011;117(7):2275–83. Cross Ref link Pubmed link
29 Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B‐cell homeostasis and excess BAFF in human chronic graft‐versus‐host disease. Blood 2009;113(16):3865–74. Cross Ref link Pubmed link
30 Schultz KR, Paquet J, Bader S, HayGlass KT. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft‐versus‐host disease. Bone Marrow Transplant 1995;16(2):289–95. Pubmed link
31 Goker H, Haznedaroglu IC, Chao NJ. Acute graft‐vs‐host disease: pathobiology and management. Exp Hematol 2001;29(3):259–77. Cross Ref link Pubmed link
32 Weaver J, Bergfeld WF. Quantitative analysis of eosinophils in acute graft‐versus‐host disease compared with drug hypersensitivity reactions. Am J Dermatopathol 2010;32(1):31–4. Cross Ref link Pubmed link
33 Levine JE, Logan BR, Wu J, et al. Acute graft‐versus‐host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012;119(16):3854–60. Cross Ref link Pubmed link
34 Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft‐versus‐host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002;8(4):410–14. Cross Ref link Pubmed link
35 Paczesny S, Braun TM, Levine JE, et al. Elafin is a biomarker of graft‐versus‐host disease of the skin. Sci Transl Med 2010;2(13):13ra2. Pubmed link
36 Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy‐resistant graft‐versus‐host disease and death. N Engl J Med 2013;369(6):529–39. Cross Ref link Pubmed link
37 Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet‐derived 3‐alpha is a biomarker of gastrointestinal graft‐versus‐host disease. Blood 2011;118(25):6702–8. Cross Ref link Pubmed link
38 Gratwohl A, Hermans J, Apperley J, et al. Acute graft‐versus‐host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood 1995;86(2):813–18. Pubmed link
39 Zhou Y, Barnett MJ, Rivers JK. Clinical significance of skin biopsies in the diagnosis and management of graft‐vs‐host disease in early postallogeneic bone marrow transplantation. Arch Dermatol 2000;136(6):717–21. Cross Ref link Pubmed link
40 Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft‐versus‐host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009;114(3):511–7. Cross Ref link Pubmed link
41 Cavet J, Middleton PG, Segall M, et al. Recipient tumor necrosis factor‐alpha and interleukin‐10 gene polymorphisms associate with early mortality and acute graft‐versus‐host disease severity in HLA‐matched sibling bone marrow transplants. Blood 1999;94(11):3941–6. Pubmed link
42 Greinix HT, Volc‐Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft‐versus‐host disease. Blood 1998;92(9):3098–104. Pubmed link
43 Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft‐versus‐host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363(9419):1439–41. Cross Ref link Pubmed link
44 Carpenter PA. How I conduct a comprehensive chronic graft‐versus‐host disease assessment. Blood 2011;118(10):2679–87. Cross Ref link Pubmed link
45 Patel AR, Pavletic SZ, Turner ML, Cowen EW. The isomorphic response in morphealike chronic graft‐vs‐host disease. Arch Dermatol 2008;144(9):1229–31. Pubmed link
46 Creamer D, Martyn‐Simmons CL, Osborne G, et al. Eczematoid graft‐vs‐host disease: a novel form of chronic cutaneous graft‐vs‐host disease and its response to psoralen UV‐A therapy. Arch Dermatol 2007;143(9):1157–62. Cross Ref link Pubmed link
47 Hymes SR, Turner ML, Champlin RE, Couriel DR. Cutaneous manifestations of chronic graft‐versus‐host disease. Biol Blood Marrow Transplant 2006;12(11):1101–13. Cross Ref link Pubmed link
48 Nagler RM, Nagler A. Salivary gland involvement in graft‐versus‐host disease: the underlying mechanism and implicated treatment. Isr Med Assoc J 2004;6(3):167–72. Pubmed link
49 Pidala J, Kurland B, Chai X, et al. Patient‐reported quality of life is associated with severity of chronic graft‐versus‐host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2011;117(17):4651–7. Cross Ref link Pubmed link
50 Kim ST, Jung CW, Lee J, et al. New clinical grading system for chronic GVHD predicts duration of systemic immunosuppressive treatment and GVHD‐specific and overall survival. Bone Marrow Transplant 2007;39(11):711–16. Cross Ref link Pubmed link
51 Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft‐versus‐host disease: association with treatment‐related mortality and relapse. Blood 2002;100(2):406–14. Cross Ref link Pubmed link
52 Kapoor N, Pelligrini AE, Copelan EA, et al. Psoralen plus ultraviolet A (PUVA) in the treatment of chronic graft versus host disease: preliminary experience in standard treatment resistant patients. Semin Hematol 1992;29(2):108–12. Pubmed link
53 Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft‐versus‐host disease. Blood 2008;112(7):2667–74. Cross Ref link Pubmed link
54 Pierelli L, Perseghin P, Marchetti M, et al. Extracorporeal photopheresis for the treatment of acute and chronic graft‐versus‐host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process. Transfusion 2013;53(10):2340–52. Pubmed link
55 de Masson A, Bouaziz JD, Peffault de Latour R, et al. Limited efficacy and tolerance of imatinib mesylate in steroid‐refractory sclerodermatous chronic GVHD. Blood 2012;120(25):5089–90. Cross Ref link Pubmed link
56 Magro L, Mohty M, Catteau B, et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft‐versus‐host disease. Blood 2009;114(3):719–22. Cross Ref link Pubmed link
57 Pintar T, Zorc‐Pleskovic R, Alessiani M, Milutinovic A, Pleskovic A. Prognostic value of skin histology in GVHD after intestinal transplantation. Eur J Pediatr Surg 2007;17:412–15. Cross Ref link Pubmed link
58 Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft‐versus‐host disease in human recipients of marrow from HL‐A‐matched sibling donors. Transplantation 1974;18:295–304. Cross Ref link Pubmed link
59 Thomas ED, Storb R, Clift RA, et al. Bone‐marrow transplantation (second of two parts). N Engl J Med 1975;292:895–902. Cross Ref link Pubmed link
60 Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft‐versus‐host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997;97:855–64. Cross Ref link Pubmed link
61 Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease: I. Diagnosis and staging working group report. Biology of blood and marrow transplantation. J Am Soc Blood Marrow Transpl 2005;11:945–56. Cross Ref link

Log in to Rooks online